Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals : Post Hoc Analysis of Japanese Patients (MELODY Study)

Koike, Takao; Harigai, Masayoshi; Ishiguro, Naoki; Inokuma, Shigeko; Takei, Syuji; Takeuchi, Tsutomu; Yamanaka, Hisashi; Takasaki, Yoshinari; Mimori, Tsuneyo; Hisamatsu, Katsutoshi; Komatsu, Shuichi; Tanaka, Yoshiya

Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals : Post Hoc Analysis of Japanese Patients (MELODY Study)

Koike, Takao; Harigai, Masayoshi; Ishiguro, Naoki et al.

Rheumatology and Therapy, 2016, 3(1), 129-141

Permalink : https://hdl.handle.net/2115/62851

このアイテムのアクセス数:1,223件（2026-08-15 13:56 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
134_art_10.1007_s40744-015-0023-x	pdf	551 KB	816
40744_2015_23_MOESM1_ESM	pdf	230 KB	473	Supporting Information

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/62851
タイトル	Effect of Methotrexate Plus Adalimumab on the Achievement of Rheumatoid Arthritis Therapeutic Goals : Post Hoc Analysis of Japanese Patients (MELODY Study)
著者	Koike, Takao ; Harigai, Masayoshi ; Ishiguro, Naoki ; Inokuma, Shigeko ; Takei, Syuji ; Takeuchi, Tsutomu ; Yamanaka, Hisashi ; Takasaki, Yoshinari ; Mimori, Tsuneyo ; Hisamatsu, Katsutoshi ; Komatsu, Shuichi ; Tanaka, Yoshiya
e-Rad_Researcher 80146795 著者名 Koike, Takao
e-Rad_Researcher 20238207 著者名 Harigai, Masayoshi
e-Rad_Researcher 20212871 著者名 Ishiguro, Naoki
著者名 Inokuma, Shigeko
著者名 Takei, Syuji
e-Rad_Researcher 50179610 著者名 Takeuchi, Tsutomu
e-Rad_Researcher 10166754 著者名 Yamanaka, Hisashi
e-Rad_Researcher 80154772 著者名 Takasaki, Yoshinari
e-Rad_Researcher 10157589 著者名 Mimori, Tsuneyo
著者名 Hisamatsu, Katsutoshi
著者名 Komatsu, Shuichi
e-Rad_Researcher 30248562 著者名 Tanaka, Yoshiya
言語	英語
キーワード	Adalimumab
	Doses
	Effectiveness
	Methotrexate
	Rheumatoid arthritis
	Safety
発行日	2016-06
出版者	Springer Healthcare
収録物名	Rheumatology and Therapy
巻(号)	3(1)
ページ	129-141
抄録	Introduction: There is insufficient evidence regarding the appropriate dose of methotrexate (MTX) required to achieve specific treatment goals in patients with rheumatoid arthritis (RA) receiving biologic drugs in Japan. The present study aimed to assess the dose-response effect of MTX in combination with adalimumab (ADA) to achieve low disease activity (LDA) and/or remission at 24 weeks in RA patients. Methods: This analysis used data of the ADA all-case survey in Japan (n = 7740), and 5494 patients who received ADA and MTX were classified into five groups by weighted average MTX dose (>0-<4, 4-<6, 6-<8, 8-< 10, and ≥10 mg/week). Of the 5494 patients, 3097 with baseline 28-joint disease activity score based on erythrocyte sedimentation rate >3.2 were analyzed for effectiveness by MTX dose. Results: In biologic-naive patients (n = 1996/3097), LDA/remission rates increased with MTX up to 6-<8 mg/week and then plateaued at higher doses (LDA, p = 0.0440; remission, p = 0.0422). In biologic-exposed patients (n = 1101/3097), LDA/remission rates increased with MTX dose (LDA, p = 0.0009; remission p = 0.0143). The incidences of serious adverse drug reactions (ADRs) and serious infections did not differ by MTX dose, but total ADRs and infections were significantly higher (p < 0.05) with increased MTX doses. Conclusion: The appropriate MTX doses in combination with ADA to achieve LDA and/or remission at week 24 were different between biologic-naive and biologic-exposed patients with RA, suggesting that 8 mg/week of MTX would be enough for biologic-naive patients.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2198-6576
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1007/s40744-015-0023-x